Michael Staehler
MD
Professor
👥Biography 个人简介
Michael Staehler at LMU Munich has contributed to renal cell carcinoma surgical oncology and adjuvant therapy research, including participation in trials of adjuvant sunitinib and pembrolizumab after nephrectomy for high-risk localized RCC. KEYNOTE-564 established pembrolizumab as the first adjuvant immunotherapy to improve disease-free survival in resected high-risk clear cell RCC, representing a major advance in early-stage treatment.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Michael Staehler 的研究动态
Follow Michael Staehler's research updates
留下邮箱，当我们发布与 Michael Staehler（LMU University Hospital Munich）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment